Inventor · disambiguated record
Rod L. Hartwig
Also filed as: HARTWIG ROD · HARTWIG ROD L · HARTWIG ROD LAWSON
12 granted patents·12 pending applications·123 citations·filing 2001–2024
89Inventor score
Top patents by PatentIndex Score
24 records- 0195US8865207B2Compositions and methods for delivering active agents in transdermal drug delivery systemsNOVEN PHARMA·Filed 2012·Granted Oct 21, 2014·22 cites·20 claims
- 0295US8343538B2Compositions and methods for controlling the flux of a drug from a transdermal drug delivery systemsNOVEN PHARMA·Filed 2005·Granted Jan 1, 2013·22 cites·42 claims
- 0394US8703175B2Compositions and methods for controlling drug loss and delivery in transdermal drug delivery systemsKANIOS DAVID P·Filed 2004·Granted Apr 22, 2014·49 cites·41 claims
- 0490US11197852B2Continuous delivery of lenalidomide and other immunomodulatory agentsSTARTON THERAPEUTICS INC·Filed 2020·Granted Dec 14, 2021·4 cites·18 claims
- 0589US7989496B2Transdermal delivery of ketoprofen polar derivativesNOVEN PHARMA·Filed 2007·Granted Aug 2, 2011·12 cites·18 claims
- 0687US9408802B1Seven day drug in adhesive transdermal deliveryPROSOLUS INC·Filed 2013·Granted Aug 9, 2016·8 cites·7 claims
- 0779US12383510B2Treatment of vomiting and nausea with minimum dose of olanzapineSTARTON THERAPEUTICS INC·Filed 2024·Granted Aug 12, 2025·0 cites·19 claims
- 0876US2025108043A1Continuous delivery of lenalidomide and other immunomodulatory agentsSTARTON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0971US8586080B1Inhibiting crystallization of steroidal hormones in transdermal delivery systemsHARTWIG ROD·Filed 2004·Granted Nov 19, 2013·6 cites·12 claims
- 1069US12201622B2Continuous delivery of lenalidomide and other immunomodulatory agentsSTARTON THERAPEUTICS INC·Filed 2021·Granted Jan 21, 2025·0 cites·18 claims
- 1167US2014243764A1Compositions and methods for controlling drug loss and delivery in transdermal drug delivery systemsNOVEN PHARMA·Filed 2014·Application pending·0 cites
- 1264US11975112B2Treatment of vomiting and nausea with minimum dose of olanzapineSTARTON THERAPEUTICS INC·Filed 2021·Granted May 7, 2024·0 cites·11 claims
- 1361US2008063698A1Crystallization inhibition of drugs in transdermal drug delivery systems and methods of useNOVEN PHARMA·Filed 2007·Application pending·0 cites
- 1460US2003152616A1Crystallization inhibition of drugs in transdermal drug delivery systems and methods of useNOVEN PHARMA·Filed 2003·Application pending·0 cites
- 1560US2025134828A1Molecular solid suspensions for transdermal drug deliverySTARTON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1657US2010310610A1Compositions and methods for controlling drug loss and delivery in transdermal drug delivery systemsNOVEN PHARMA·Filed 2010·Application pending·0 cites
- 1756US2002106402A1Crystallization inhibition of drugs in transdermal drug delivery systems and methods of useFiled 2001·Application pending·0 cites
- 1855US2022395468A1Transdermal Drug Delivery Systems for Administration of a Therapeutically Effective Amount of Lenalidomide and Other Immunomodulatory AgentsSTARTON THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1954US2024009204A1Treatment of Vomiting and Nausea with Minimum Dose of OlanzapineSTARTON THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2053US12390457B2Stable solutions of immunomodulatory imide compounds for parenteral useSTARTON THERAPEUTICS INC·Filed 2022·Granted Aug 19, 2025·0 cites·6 claims
- 2146US2004142023A1Crystallization inhibition of drugs in transdermal drug delivery systems and methods of useNOVEN PHARMA·Filed 2004·Application pending·0 cites
- 2246US2011263705A1Transdermal delivery of ketoprofen polar derivatesNOVEN PHARMA·Filed 2011·Application pending·0 cites
- 2345US10010511B2Transdermal drug delivery systemPROSOLUS INC·Filed 2016·Granted Jul 3, 2018·0 cites·20 claims
- 2438US2013211351A1Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amineGRUENENTHAL GMBH·Filed 2013·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →